[1] |
Vogel A, Meyer T, Sapisochin G, et al. Hepatocellular carcinoma[J]. Lancet, 2022, 400(10360):1345-1362.
|
[2] |
Villanueva A. Hepatocellular carcinoma[J]. N Engl J Med, 2019, 380(15):1450-1462.
|
[3] |
Kulik L, El-Serag HB. Epidemiology and management of hepatocellular carcinoma[J]. Gastroenterology, 2019, 156(2):477-491, e1.
|
[4] |
Chidambaranathan-Reghupaty S, Fisher PB, Sarkar D. Hepatocellular carcinoma (HCC): epidemiology, etiology and molecular classification[J]. Adv Cancer Res, 2021, 149: 1-61.
|
[5] |
Wu M, Yang G, Chen Y, et al. CEP2 attenuates myoblast differentiation but does not affect proliferation[J]. Int J Biol Sci, 2015, 11(1):99-108.
|
[6] |
Bryan BA, Li D, Wu X, et al. The Rho family of small GTPases: crucial regulators of skeletal myogenesis[J]. Cell Mol Life Sci, 2005, 62(14):1547-1555.
|
[7] |
Wang T, Rao D, Yu C, et al. RHO GTPase family in hepatocellular carcinoma[J]. Exp Hematol Oncol, 2022, 11(1):91.
|
[8] |
Chan W, Kozma R, Yasui Y, et al. Vimentin intermediate filament reorganization by Cdc42: involvement of PAK and p70 S6 kinase[J]. Eur J Cell Biol, 2002, 81(12):692-701.
|
[9] |
Fife CM, McCarroll JA, Kavallaris M. Movers and shakers: cell cytoskeleton in cancer metastasis[J]. Br J Pharmacol, 2014, 171(24):5507-5523.
|
[10] |
Liu D, Song T. Changes in and challenges regarding the surgical treatment of hepatocellular carcinoma in China[J]. Biosci Trends, 2021, 15(3):142-147.
|
[11] |
Ganesan P, Kulik LM. Hepatocellular carcinoma: new developments[J]. Clin Liver Dis, 2023, 27(1):85-102.
|
[12] |
Wang W, Wei C. Advances in the early diagnosis of hepatocellular carcinoma[J]. Genes Dis, 2020, 7(3):308-319.
|
[13] |
张超,陈卓妙语,程倩, 等. ARID1A在肝内胆管癌患者中的表达及与肿瘤微环境的关系[J]. 中华普通外科杂志, 2023, 38(5):362-366.
|
[14] |
Di Ciano-Oliveira C, Thirone ACP, Szászi K, et al. Osmotic stress and the cytoskeleton: the R(h)ole of Rho GTPases[J]. Acta Physiol, 2006, 187(1/2):257-272.
|
[15] |
Hirsch DS, Pirone DM, Burbelo PD. A new family of Cdc42 effector proteins, CEPs, function in fibroblast and epithelial cell shape changes[J]. J Biol Chem, 2001, 276(2):875-883.
|
[16] |
Calvo F, Ranftl R, Hooper S, et al. Cdc42EP3/BORG2 and septin network enables mechano-transduction and the emergence of cancer-associated fibroblasts[J]. Cell Rep, 2015, 13(12):2699-2714.
|
[17] |
Ageta-Ishihara N, Yamazaki M, Konno K, et al. A CDC42EP4/septin-based perisynaptic glial scaffold facilitates glutamate clearance[J]. Nat Commun, 2015, 6: 10090.
|
[18] |
Farrugia AJ, Rodríguez J, Orgaz JL, et al. CDC42EP5/BORG3 modulates SEPT9 to promote actomyosin function, migration, and invasion[J]. J Cell Biol, 2020, 219(9):e201912159.
|
[19] |
Joberty G, Perlungher RR, Macara IG. The Borgs, a new family of Cdc42 and TC10 GTPase-interacting proteins[J]. Mol Cell Biol, 1999, 19(10):6585-6597.
|
[20] |
Burbelo PD, Snow DM, Bahou W, et al. MSE55, a Cdc42 effector protein, induces long cellular extensions in fibroblasts[J]. Proc Natl Acad Sci U S A, 1999, 96(16):9083-9088.
|
[21] |
Farrugia AJ, Calvo F. Cdc42 regulates Cdc42EP3 function in cancer-associated fibroblasts[J]. Small GTPases, 2017, 8(1):49-57.
|